This study is a multicenter, non-interventional, retrospective, medical chart review of participants with metastatic renal cell cancer(mRCC) treated with avelumab plus axitinib as a first-line therapy in Japan between 20 December 2019 and 17 October 2022. All decisions regarding clinical management and treatment of the participating patients were made by the investigator as part of standard care in real-world clinical setting and were not contingent upon the patient's participation in the study. Data will be collected if available per study site.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Age of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Height of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Body Weight of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Body Mass Index of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
C-Reactive Protein Levels of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Estimated Glomerular Filtration Rate of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Smoking History Status of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Eastern Cooperative Oncology Group (ECOG) Performance Scale Score Status of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Number of Participants With Metastatic Organs at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Invasion Depth (T Factor) of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Lymph Node Metastasis (N Factor) Status of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Distant Metastasis (M Factor) Status of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Tumor Histological Type of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Number of Participants With Presence or Absence of Sarcomatoid Component in Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Fuhrman Grade Status of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Availability of Proteinuria in Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Performance of Nephrectomy in Participants
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Number of Participants With Presence or Absence of Clinically Important Comorbidities of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Number of Participants With Presence or Absence of Clinically Important Concomitant Drugs in Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Number of Participants With Initiation of Systemic Therapy Within One Year of Diagnosis
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Number of Participants With Karnofsky Performance Status Less Than (<) 80 Percent (%) at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Number of Participants With Hemoglobin Value Below the Lower Normal Limit at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Number of Participants With Corrected Calcium Value Above the Upper Normal Limit in Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Number of Participants With Neutrophil Count Above the Upper Normal Limit in Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
International Metastatic RCC Database Consortium (IMDC) Risk Group in Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Number of Risk Factors in Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)